DOCSLIB.ORG

(ADHD): Part II. Guanfacine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(ADHD): Part II. Guanfacine PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children’s Hospital Volume 1 4 Number 4 April 20 08 New Treatment Options for Attention -Deficit/Hyperactivity Disorder (ADHD) : Part I I. Guanfacine Marcia L. Buck, Pharm.D., FCCP lonidine and g uanfacine, alpha -2A total of 34 children (mean age 10.4 years) with C adrenergic agonist s, ha ve been used off - ADHD and a tic disorder were randomized to label in the management of children with receive either guanfacine, beginning with 0.5 mg attention -de ficit/hyperactivity disorder (ADHD) and titrated as needed, or placebo for 8 weeks. for more than a decade . Guanfacine is preferred The effective dose of guanfacine ranged from 1.5 by many health care providers for its longer to 3 mg /day. Guanfacine produced a duration of action. 1,2 A new extended -release significantly greater improvement in ADHD formulation of guanfacine is currently under Rating Scale scores (37% versus 8% in the review by the Food and Drug Admin istration controls , p<0.001) . Clinical Global (FDA) specifically for the treatment of ADHD in Improvement (CGI) scale scores were rated as children between 6 and 1 7 years of age. 3 This much improved or very much improved in 9 of issue of Pediatric Pharmacotherapy will provide the 17 guanfacine patients, while none of the a basic review of guanfacine and highlight recent placebo patients achieved these scores studies of both the immediate -release and the (p<0.001). In addition, tic severity decreased by new ex tended -release product. 31% in the guanfacine group, with no improvement in the placebo group using the Yale Mechanism of Action Global Tic Severity Scale ( p=0.05). There w as Guanfacine, like clonidine, is a centrally acting no significant difference between the groups in selective alpha -2 adrenergic agonist. Stimulation mean p arent -rated hyperactivity index score s, of alpha -2 adrenergic receptors in the prefrontal with a 27% improvement in the guanfacine group cortex results in enhanced executive functioning, and a 21% improvement in the placebo group. increase d attentiveness, and improvements in working memory. In patients with ADHD, In 2001, Taylor and Russo conducted a improved neurotransmission in this region comparison study of guanfacine and increases the ability to control or inhibit dextroamphetamine in adults with ADHD. 8 inappropriate behaviors and increase focus. Seventeen adults were enrolled into this Guanfacine preferentially bind s alpha -2A randomized, double -blind, placebo -controlled receptor s, compared to the more general affinity crossover study. The subjects received each of clonidine for alpha -2A, B, and C and treatment (0.25 mg guanfacine, 2.5 mg imidazoline receptors. 1,2 dextroamphetamine, or placebo) for a 2 week period separated by 4 day wash -outs. Doses Clinical Studies in Children were titrated to achieve symptom control, up to a maximum of 2 mg guanfacine or 20 mg Immediate -release Guanfacine dextroamphetamine. The average final daily The first studies of guanfacine in children with dose s were 1.1 mg guanfacine and 10.2 mg ADHD were published in 1995. 4-6 These three dextroamphetamine . small open -label studies demonstrated the efficacy of immediate -release guanfacine in Both drugs signifi cantly reduced ADHD improving ADHD symptoms and served as a symptoms compared to baseline, using the foundation for further research . The first ADH D Behavior Checklist for Adults (p<0.05). placebo -controlled guanfacine trial was The only significant difference between the published by Scahill and colleagues in 2001. 7 A results achieved with the two drugs was in the Color -Word subscale of the Controlled Oral distribution throughout the body. Guanfacine is Word Associatio n Test, where guanfacine metabolized via hepatic conjugation. The parent produced a greater degree of improvement compound and metabolites are excreted in the (p<0.01). 8 urine. The elimination half -life of immediate - release guanfa cine is approximately 1 0 to 17 Two additional studies have evaluated the effects hours in adults .2 of guanfacine in children with pervasive developmental disorders (PDD) and ADH D or In 2007, Swearingen and colleagues conducted a hyperactivity. 9,10 In 2004, Posey and coll eagues Phase I open -label single -dose pharmacokinetic conducted a retrospective study in 80 children study of extended -release guanfacine in 52 9 12 (3 -18 years of age) who received guanfacine. adults . The maximum serum concentrations The authors found a response rate of 23.8% (C max ) ranged from 0.98 +0.26 ng/mL with a 1 mg (19/80), using an average dose of 2.6 +1.7 dose to 3.58 +1.39 ng/mL with the 4 mg dose. mg/day. The children most likely to respond to Area under the concentration -time curve (AUC 0- -1 guanfacine were those with PDD alone or in ) ranged from 32.4 +8.78 ng/mL ·h for the 1 mg combination with Asperger’s. Patients with co - dose to 124.1 +45.1 ng/mL ·h-1 for the 4 mg dose. morbid autism or mental retardation were less The average elimination half -life ranged fro m likely to benefit from treatment. 16.6 +3.8 to 17.5 +3.8 hours . Scahill and colleagues conducted a prospective The pharmacokinetic profile of extended -release open -label study of guanfacine in 25 children guanfacine was also recently studied in a group with PDD -ass ociated hyperactivity. 10 After 8 of 14 children (6 -12 years of age) and 14 weeks of treatment, there was significant adolescents (12 -17 years of age). 13 All subjects improvement in parent -rated hyperactivity using received a single 2 mg dose on the first day of the Aberrant Behavior Checklist , a decline from the study, followed by a wash -out period, then 31.1 +8.89 at baseline to 18.9 +10.37 at study sequential doses of 2 mg, 3 mg, and 4 mg each completion ( p<0.001). The teacher -rate d scores for a week. After the 2 mg dose, the younger also declined, from 29.9 +9.12 at baseline to children achieved a higher AUC 0-, with an 22.3 +9.44 (p<0.01). Forty -eight percent of the average of 62.5 +23.9 ng ·hr/mL compared to children achieved a rating of much improved or 47.3 +13.7 ng ·hr/mL in the adolescents. Time to very much improved on their CGI scores. The maximum plasma concentration was average final dose in this study ranged from 1 to approximately 5 hours for both age groups. The 3 mg/day. Cmax increased proportionally to the dose, with the 2 mg dose producing C max values of Ex tended -release Guanfacine 4.39 +1.66 ng/mL and 2.86 +0.77 ng/mL in the In the January 2008 issue of Pediatrics , younger and older groups, respectively. For Biederman and colleagues published the results comparison, a week of treatment with the 4 mg of a randomized, double -blind, placebo - dose produced C max values of 10.1 +7.09 ng/L controlled trial of extended -release guanfacine in and 7.01 +1.53 ng/mL. The average elimination children with ADHD. 11 A total of 345 children half -life was 14.4 +2.39 hours in younger children betwe en 6 and 17 years of age were enrolled in and 17.9 +5.77 hours in adolescents. this multicenter study. Patients were randomized to receive extended -release guanfacine (at a dose Drug Interactions of 2 mg, 3 mg, or 4 mg) or placebo once daily. Administration of guanfacine with other central There was significant improvement in ADHD nervous system depressants may result in Rating Scale total score s in each of the three excessive sedation. 1,2 treatment groups, with a mean reduction at endpoint of -16.7 compared to -8.9 for the Contraindications /Precautions placebo group (p < 0.0001) . Significant Abrupt discontinuation of guanfacine may result improvement in CGI scores was demonstrated in in increased levels of serum catecholamines. In 55.95% of the 2 mg group, 50% of the 3 mg comparison to clonidine, guanfacine produces group, and 55.56% of the 4 mg group, compared less of an effect on blood pressure because of its to only 25.64% of the placebo group. weaker binding affinity for imidazoline receptors. In patients taking guanfacine for Pharmacokinetics hypertension, abrupt discontinuation has result ed Immediate -release guanfacine is well absorbed, in mild rebound hypertension, anxiety, and with an oral bioavailability of approximately irritability. I t is recommended that guanfacine 80%. Peak concentrations occur 1 -4 hours after doses be slowly tapered over a period of several an oral dose. It has a large vo lume of weeks to avoid these effects. 1,2 distribution, 6.3 L/kg, reflecting extensive The incidence of rebound hyper tension with In 1999, Horrigan and Barnhill published a case guanfacine discontinuation in patients wi th series of five children who develop ed symptoms ADHD appears to be low . Kisicki and of mania after being treated with guanfacine. 15 colleagues compared abrupt discontinuation of Symptoms began 1 to 3 days after starting extended -release guanfacine to a taper in 45 therapy and resolved with discontinuation of healthy young adults (ages 19 -24 years). 14 All therapy. All of the children had developmental subjects received a sta ndardized dose -escalation, disorders in addition to ADHD and several had starting with 1 mg extended -release guanfacine risk factors for bipolar disorder, which may have followed by a 1 mg increase every 4 days. placed them at higher risk for this adverse effect.
Load more

Recommended publications
  • Switching from Clonidine Immediate-Release to Guanfacine Extended-Release
    / DE L’ACADÉMIE CANADIENNE DE PSYCHIATRIE DE L’ENFANT ET DE L’ADOLESCENT PSYCHOPHARMACOLOGY Switching from Clonidine Immediate-Release to Guanfacine Extended-Release Dean Elbe PharmD, BCPP1,2,3 s a clinical pharmacy specialist in child and adolescent (Canada) Ltd, 2012b). Clonidine has been used off-label Amental health, I am frequently asked how to switch in children for many years for treatment of insomnia, patients from clonidine immediate-release (IR) to guanfa- ADHD, and disruptive behaviour disorders (Hunt, Capper cine extended-release (XR). This therapeutic switch may be & O’Connell, 1990; Rubinstein; Jaselskis, Cook, Fletcher required when poor adherence to a clonidine IR regimen & Leventhal, 1992; Silver & Licamele, 1994; Palumbo et (typically requiring 3–4 doses daily) is identified, when al., 2008; Efron, Lycett & Sciberras, 2014). A clonidine XR clonidine dose-optimization is limited by sedation, brady- formulation is not available in Canada, but is available in cardia or hypotension, or when coverage situations change. the United States for treatment of ADHD (Concordia Phar- The latter may occur if, for example, new eligibility for a maceuticals, Inc. 2015). government program or a third party-payer occurs. Weight-based dosing guidelines exist for clonidine IR Guanfacine XR, a selective alpha2A agonist, was first mar- (0.003–0.008 mg/kg/day) and guanfacine XR (0.05–0.08 keted in Canada in late 2013 for the treatment of attention mg/kg/day) (Shire Pharma Canada ULC, 2019; Elbe et deficit hyperactivity disorder (ADHD) in children and ado- al., 2018). Based on these guidelines and other literature, lescents (Shire Pharma Canada ULC, 2019).
    [Show full text]
  • Memory Deficits Associated with Clonidine
    Letter to the Editor Letters to the Editor are invited for comment on a topic of current interest or on Table material published in GENERAL HOSPITAL PSYCHIATRY. Letters should be typed doubled spaced and are subject to editing according to space limitations. - Memory Deficits Associated with Attent KnO Clonidine WA Verbal WA Drugs used in the treatment of essential hyperten- Initiation of clonidine therapy (0.1 mg b.i.d.) in WA sion are among the most commonly prescribed. April 1984 resulted in well-controlled hypertension Tactilc Some of these agents have primary effects on neu- without immediately apparent adverse effects. Fulc rotransmitter systems and are centrally active. However, the coincidence of the onset of memory Verba Thus, drugs such as a-methyldopa, propranalol, complaints and the beginning of clonidine treat- 3% ment suggested that clonidine might be respon- List Ll and reserpine have well-established neuropsychia- Fulc tric complications, ranging from depression to cog- sible. si nitive impairments and psychosis [l].Since the use After consultation with the patient's internist, a R of these drugs is widespread and unavoidable, we switch was made to captopril, an angiotensin-con- T must be alert to the possibility that these drugs verting enzyme inhibitor. Before the change we T administered tests of attention, concentration, and contribute to psychologic complaints and symp- -R toms of our patients. verbal skills as well as the Fuld Object-Memory Evaluation, which includes a measure of verbal 'Age-a Clonidine, a presynaptic adrenergic a2agonist, bNonc has become well established as a useful and rela- fluency as well as a selective reminding list learning tively safe therapeutic agent.
    [Show full text]
  • Sleep & Dreams & Dsm-5
    PAL Conference - Green River, WY - May 2015 SLEEP & DREAMS & DSM-5: ASSESSMENT AND TREATMENT OF PEDIATRIC INSOMNIA James Peacey, MD PAL Conference Green River, WY Disclosure Statement No relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial services discussed in this CME activity. I will reference off-label or investigational use of medications in this presentation. PAL Conference - Green River, WY - May 2015 Goals and Objectives Learn how to identify and categorize pediatric insomnia. Increase knowledge of common behavioral and pharmacologic sleep treatments. Increase understanding of sleep issues in particular patient populations (Autism, ADHD, depression and anxiety) and appropriate strategies to optimize treatment. PAL Conference - Green River, WY - May 2015 Sleep Stage Development PAL Conference - Green River, WY - May 2015 Homeostatic and Circadian Processes D. J. Dijk and D. M. Edgar, Regulation of Sleep and Wakefulness, 1999 PAL Conference - Green River, WY - May 2015 Homeostatic and Circadian Processes PAL Conference - Green River, WY - May 2015 Alerting Systems PAL Conference - Green River, WY - May 2015 Normal Sleep Requirements Babcock, Pediatr Clin N Am 58 (2011) 543–554PAL Conference - Green River, WY - May 2015 Percentiles for total sleep duration per 24 hours from infancy to adolescence. Iglowstein I et al. Pediatrics 2003;111:302-307 PAL Conference - Green River, WY - May 2015 ©2003 by American Academy of Pediatrics Insomnia “significant difficulty initiating
    [Show full text]
  • Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: a Literature Review
    medical sciences Review Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: A Literature Review Sachin Relia 1,* and Vijayabharathi Ekambaram 2,* 1 Department of Psychiatry, University of Tennessee Health Sciences Center, 920, Madison Avenue, Suite 200, Memphis, TN 38105, USA 2 Department of Psychiatry, University of Oklahoma Health Sciences Center, 920, Stanton L Young Blvd, Oklahoma City, OK 73104, USA * Correspondence: [email protected] (S.R.); [email protected] (V.E.); Tel.: +1-901-448-4266 (S.R.); +1-405-271-5251 (V.E.); Fax: +1-901-297-6337 (S.R.); +1-405-271-3808 (V.E.) Received: 15 August 2018; Accepted: 17 October 2018; Published: 25 October 2018 Abstract: Autism is a developmental disability that can cause significant emotional, social and behavioral dysfunction. Sleep disorders co-occur in approximately half of the patients with autism spectrum disorder (ASD). Sleep problems in individuals with ASD have also been associated with poor social interaction, increased stereotypy, problems in communication, and overall autistic behavior. Behavioral interventions are considered a primary modality of treatment. There is limited evidence for psychopharmacological treatments in autism; however, these are frequently prescribed. Melatonin, antipsychotics, antidepressants, and α agonists have generally been used with melatonin, having a relatively large body of evidence. Further research and information are needed to guide and individualize treatment for this population group. Keywords: autism spectrum disorder; sleep disorders in ASD; medications for sleep disorders in ASD; comorbidities in ASD 1. Introduction Autism is a developmental disability that can cause significant emotional, social, and behavioral dysfunction. According to the Diagnostic and Statistical Manual (DSM-V) classification [1], autism spectrum disorder (ASD) is characterized by persistent deficits in domains of social communication, social interaction, restricted and repetitive patterns of behavior, interests, or activities.
    [Show full text]
  • Data Sheet SURMONTIL Trimipramine (As Maleate) 25 Mg Tablets and 50 Mg Capsules
    Data Sheet SURMONTIL trimipramine (as maleate) 25 mg tablets and 50 mg capsules Presentation SURMONTIL tablets are compression coated, white or cream, circular, biconvex, containing the equivalent of 25mg trimipramine (as maleate) with a diameter of about 8.0mm. The face is indented with the name and strength, reverse plain. SURMONTIL capsules are opaque white with opaque green cap, printed SU50, each containing the equivalent of 50mg trimipramine (as maleate). Uses Actions SURMONTIL has a potent anti-depressant action similar to that of other tricyclic anti-depressants. The mechanism of action is not fully understood but it is thought to be via inhibition of neuronal re- uptake of noradrenalin, thereby increasing availability. SURMONTIL also possesses a pronounced sedative action. Pharmacokinetics SURMONTIL is readily absorbed after oral administration, reaching a mean peak plasma level after 3 hours. High first pass hepatic clearance results in a mean bioavailability of about 41% of the oral dose, and trimipramine is extensively protein bound in plasma. Elimination half-life is 24 hours. Metabolism is in the liver to its major metabolite, desmethyltrimipramine, which is excreted mainly in the urine. Indications SURMONTIL is indicated in the treatment of depressive illness, especially where sleep disturbance, anxiety or agitation is a presenting symptom. Sleep disturbance is controlled within 24 hours and true anti-depressant action follows within 7-10 days. Dosage and Administration Adults Mild/Moderate Depression in General Practice: The recommended dosage is 50-75 mg orally given two hours before bedtime, the larger dose (75 mg) being preferable for those patients with more marked sleep disturbance.
    [Show full text]
  • Effects of Sympathetic Inhibition on Receptive, Proceptive, and Rejection Behaviors in the Female Rat
    Physiology & Behavior, Vol. 59, No. 3, pp. 537-542, 1996 Copyright © 1996 Elsevier Science Inc. Printed in the USA. All rights reserved 0031-9384/96 $15.00 + .00 ELSEVIER 0031-9384(95)02102-2 Effects of Sympathetic Inhibition on Receptive, Proceptive, and Rejection Behaviors in the Female Rat CINDY M. MESTON, 1 INGRID V. MOE AND BORIS B. GORZALKA Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver, British Columbia, Canada V6T 1Z4 Received 27 September 1994 MESTON, C. M., I. V. MOE AND B. B. GORZALKA. Effects of sympathetic inhibition on receptive, proceptive, and rejection behaviors in the female rat. PHYSIOL BEHAV 59(3) 537-542, 1996.--The present investigation was designed to examine the effects of sympathetic nervous system (SNS) inhibition on sexual behavior in ovariec- tomized, steroid-treated female rats. Clonidine, an alpha2-adrenergic agonist, guanethidine, a postganglionic noradren- ergic blocker, and naphazoline, an alpha2-adrenoreceptor agonist were used to inhibit SNS activity. Intraperitoneal injections of eit:aer 33/zg/ml or 66/xg/ml clonidine significantly decreased receptive (lordosis) and proceptive (ear wiggles) behaviors and significantly increased rejection behaviors (vocalization, kicking, boxing). Either 25 mg/ml or 50 mg/ml guanethidine significantly decreased receptive and proceptive behavior and had no significant effect on rejection behav!iors. Naphazoline significantly inhibited lordosis behavior at either 5 mg/ml or 10 mg/ml doses, significantly inhibited proceptive behavior at 5 mg/ml, and had no significant effect on rejection behaviors. These findings supporc the hypothesis that SNS inhibition decreases sexual activity in the female rat. Lordosis Proceptive behavior Rejection behavior Clonidine Guanethidine Naphazoline Alpha-adrenergic INTRODUCTION as 2 /xg/animal also inhibits lordosis behavior (1).
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Do These Fearful and Aggressive Dogs Need Drugs? Gary Landsberg, DVM, Bsc, DACVB, DECVB-CA North Toronto Veterinary Behaviour Specialty Clinic Thornhill, Canada
    Do these Fearful and Aggressive Dogs Need Drugs? Gary Landsberg, DVM, BSc, DACVB, DECVB-CA North Toronto Veterinary Behaviour Specialty Clinic Thornhill, Canada In this seminar Dr. Landsberg will collaborate with a colleague to discuss real cases of canine aggression cases and the selection and use of drugs and natural supplements for these cases. Therefore the summary below provides a brief overview of drug selection and use. Pharmacotherapy and canine aggression When a dog is excessively aroused, fearful, anxious, overly reactive lacking impulse control or “behaviorally abnormal”, psychotropic medications are indicated to improve the problem as well as address the dog’s well-being. However, drugs do not change the relationship with the stimulus; therefore, concurrent behavior modification is needed to desensitize, countercondition and train desirable. Selective serotonin reuptake inhibitors might be most effective for hyperactivity, aggression, social anxiety, generalized fear and anxiety and panic disorders. Four weeks or longer is generally required to achieve full therapeutic effects. Starting the medication at the time of the consultation allows time for the drug to reach optimal therapeutic effect when the exposure program begins. Medication might not be required for dogs that can be effectively kept away from fear- evoking situations, provided the dog is sufficiently settled and relaxed. Adjunctive medication to further reduce anxiety especially prior to stimulus exposure might include benzodiazepines, trazodone, clonidine or propranolol, alone or in combination. If effective these drugs might be used several times a day. Psychotropic drugs Selective serotonin reuptake inhibitors (SSRI) are most commonly used in dogs that are behaviorally abnormal, to control reactivity and impulsivity, reduce fear and anxiety and improve trainability as well as address the dog’s behavioral well-being.
    [Show full text]
  • Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain
    Neuropsychopharmacology (2009) 34, 651–661 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain ,1 1 1,2 O Chernoloz* , M El Mansari and P Blier 1 2 Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ontario, Canada Pramipexole (PPX) is a D2/D3 receptor agonist that has been shown to be effective in the treatment of depression. Serotonin (5-HT), norepinephrine (NE) and dopamine (DA) systems are known to be involved in the pathophysiology and treatment of depression. Due to reciprocal interactions between these neuronal systems, drugs selectively targeting one system-specific receptor can indirectly modify the firing activity of neurons that contribute to firing patterns in systems that operate via different neurotransmitters. It was thus hypothesized that PPX would alter the firing rate of DA, NE and 5-HT neurons. To test this hypothesis, electrophysiological experiments were carried out in anesthetized rats. Subcutaneously implanted osmotic minipumps delivered PPX at a dose of 1 mg/kg per day for 2 or 14 days. After a 2-day treatment with PPX the spontaneous neuronal firing of DA neurons was decreased by 40%, NE neuronal firing by 33% and the firing rate of 5-HT neurons remained unaltered. After 14 days of PPX treatment, the firing rate of DA had recovered as well as that of NE, whereas the firing rate of 5-HT neurons was increased by 38%.
    [Show full text]
  • Clonidine for Hypertensive Urgency 11.20.17
    During a hypertensive urgency do you have any insight into the use of clonidine for acute lowering of blood pressure in the outpatient setting? Is this in any guideline? Are there alternatives? Clonidine is a centrally-acting alpha-2 agonist approved by the Food and Drug Administration (FDA) for several uses.1-5 The drug is available in multiple preparations: immediate-release (IR) and extended- release (ER) oral tablets, transdermal films, and epidural solution. The IR tablets and transdermal films are approved for management of hypertension, alone or in combination with other antihypertensive agents.2,3 In contrast, the ER tablets are approved for treatment of attention deficit hyperactivity disorder,4 and the epidural solution is approved for treatment of severe pain that is inadequately relieved by opioids, alone, in patients with cancer.5 Hypertension, defined as high blood pressure (BP), is the single most common risk factor for cardiovascular disease and is 1 of the most common reasons for ambulatory clinic visits by adults worldwide.6 Patients with hypertension may be at risk for hypertensive crises, defined as large elevations in systolic BP (>180 mmHg) or diastolic BP (>120 mmHg) associated with impending or progressive organ damage.7-9 Hypertensive crises include hypertensive emergencies or hypertensive urgencies; emergencies are associated with target organ damage while urgencies are not.7 Guidelines There are several guidelines for the management of hypertension, listed in Table 1.6,8,10-15 Use of clonidine for treatment
    [Show full text]
  • Clonidine, Lofexidine and Similar Medications for the Management of Opioid Withdrawal
    Cochrane Database of Systematic Reviews Alpha2-adrenergic agonists for the management of opioid withdrawal (Review) Gowing L, Farrell M, Ali R, White JM Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD002024. DOI: 10.1002/14651858.CD002024.pub5. www.cochranelibrary.com Alpha2-adrenergic agonists for the management of opioid withdrawal (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Alpha2-adrenergic agonists for the management of opioid withdrawal Linda Gowing1, Michael Farrell2, Robert Ali1, Jason M White3 1Discipline of Pharmacology, University of Adelaide, Adelaide, Australia. 2National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. 3School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia Contact address: Linda Gowing, Discipline of Pharmacology, University of Adelaide, Frome Road, Adelaide, South Australia, 5005, Australia. [email protected]. Editorial group: Cochrane Drugs and Alcohol Group. Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 5, 2016. Review content assessed as up-to-date: 7 January 2016. Citation: Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD002024. DOI: 10.1002/14651858.CD002024.pub5. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ABSTRACT Background Withdrawal is a necessary step prior to drug-free treatment or as the endpoint of long-term substitution treatment.
    [Show full text]
  • 65 © Elsevier/North-Holland Biomedical Press MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC AGONISTS RESTORE MOTOR AC
    Brain Research, 202 (1980) 65-77 65 © Elsevier/North-Holland Biomedical Press MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC AGONISTS RESTORE MOTOR ACTIVITY BUT PHENYLETHYLAMINE RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST ACTIVITY C. I-I. VANDERWOLF,T. E. ROBINSON and B. A. PAPPAS Department of Psychology, University of Western Ontario, London, Ontario, N6A 5C2 (Canada), ( T.E.R.) University of Michigan, Ann Arbor, Mich. 48109 (U.S.A.) and ( B.A.P.) Carleton University, Ottawa, KI S 5B6 (Canada) (Accepted May 29th, 1980) Key words: reserpine -- monoamines -- motor activity -- atropine -- neocortical activity SUMMARY A large dose of reserpine abolishes an atropine-resistant form of neocortical low voltage fast activity (LVFA) which normally accompanies certain patterns of motor activity in rats. An attempt was made to reverse this effect by replacement of specific monoamines or by injection of suitable agonists in rats pretreated with reserpine (10 mg/kg). The following compounds, alone or in various combinations, failed to restore atropine-resistant LVFA in reserpinized rats even though spontane- ous motor activity was restored in many cases: L-DOPA (150--300 mg/kg) after pretreatment with an inhibitor of peripheral L-aromatic amino acid decarboxylase; 5- hydroxytryptophan (100-200 mg/kg); D-amphetamine (1-2 mg/kg); apomorphine (0.25-2.5 mg/kg); lysergic acid diethylamide (100-300/~g/kg); and clonidine (0.5-1.0 mg/kg). In contrast fl-phenylethylamine was quite effective in restoring atropine- resistant LVFA and its effects were not diminished by pretreatment with a-methyl-p- tyrosine (400 mg/kg), chlorpromazine (15 mg/kg) or trifluoperazine (5-10 mg/kg).
    [Show full text]